Genetic silencing of MMP-3, also referred to as stromelysin-1, reduced tumor progression and angiogenesis in mouse models of BM-PCa, and MMP-3 has been shown to play a role in migration in other cancer types, including breast cancer and osteosarcoma (67–69). Here, MMP3 is linked to breast carcinoma.